Evidence map›Paper›PMID 42029984›Full record

ArticleJournal of cancer research and clinical oncology2026

LncRNA-LINC01281 exerts anti-cancer functions via the MYC/VEGF pathway in the progression of cervical cancer.

Zhang Shuqian, Chen Zhi, Quratul Ain, Liu Yan, Luo Chengfang, Bai Xiaoxu, Zhang Song, Gao Jiayin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zhang Shuqian *Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Chen Zhi *Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Quratul Ain *Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Liu YanDepartment of Obstetrics and Gynecology, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Luo ChengfangDepartment of Obstetrics and Gynecology, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Bai XiaoxuDepartment of Obstetrics and Gynecology, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Zhang SongDepartment of Hospital Record, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Gao JiayinDepartment of Obstetrics and Gynecology, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China. gaoguimeizi1@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionCervical cancer is the fourth most common cancer in women and remains a major global health issue. Long non-coding RNAs (lncRNAs) play a crucial role in tumor biology regulation. This study investigates the role of LINC01281 in cervical cancer.

methodsLncRNAs were identified from The Cancer Genome Atlas (TCGA) database, focusing on LINC01281 for detailed analysis. GSEA revealed MYC-mediated VEGF signaling as a potential pathway. Functional assays in HeLa cells assessed the impact of LINC01281 overexpression and knockdown on proliferation, migration, and the MYC-VEGFA pathway.

resultsLINC01281 is identified as a unique prognostic marker for cervical cancer. GSEA indicated participation in VEGF signaling through MYC modulation. LINC01281 overexpression inhibited MYC expression, leading to reduced cell proliferation and migration. MYC silencing led to a decreased expression of VEGFA at both transcript and protein levels. LINC01281 encodes a 42-amino acid peptide, highlighting its biological significance.

conclusionLINC01281 influences cervical cancer progression via the MYC-VEGFA pathway and may serve as a potential biomarker and therapeutic target. The lncRNA and its peptide show promise for use in cervical cancer treatment.

Indexed as

Proto-Oncogene Proteins c-mycRNA, Long NoncodingUterine Cervical NeoplasmsVascular Endothelial Growth Factor ACell MovementCell ProliferationDisease ProgressionFemaleGene Expression Regulation, NeoplasticHeLa CellsHumansSignal TransductionMYC protein, humanProto-Oncogene Proteins c-mycRNA, Long NoncodingVascular Endothelial Growth Factor AVEGFA protein, humanBioinformatics analysisCervical cnacerEnrichment analysisLncRNAWestern blot

Identifiers

PMID42029984
PMCPMC13109478

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.